Authors: | Shingarev, R.; Jaimes, E. A. |
Article Title: | Renal cell carcinoma: New insights and challenges for a clinician scientist |
Abstract: | There is a growing recognition of the complex interplay between renal cell cancer (RCC), kidney function, mechanical reduction of nephron mass, and systemic agents targeting the cancer. Earlier detection of RCC and rising life expectancy of cancer survivors places a greater emphasis on preservation of renal function after cancer resection and during systemic therapy. Unique adverse effects associated with RCC drugs not only help reveal cancer pathophysiology but also expand our knowledge of normal cell signaling and metabolism. In this review, we outline our current understanding of RCC biology and treatment, their bidirectional relationship with kidney function, and unmet research needs in this field. © 2017 the American Physiological Society. |
Keywords: | cancer surgery; unclassified drug; overall survival; review; postoperative period; angiogenesis inhibitor; nonhuman; cancer staging; cancer diagnosis; kidney carcinoma; kidney function; glomerulus filtration rate; cancer epidemiology; papillary carcinoma; mammalian target of rapamycin inhibitor; antigen presenting cell; scientist; molecularly targeted therapy; immune checkpoint inhibitor; human; priority journal; immune checkpoint inhibition; radical and partial nephrectomy; renal cell carcinoma genotyping |
Journal Title: | American Journal of Physiology - Renal Physiology |
Volume: | 313 |
Issue: | 2 |
ISSN: | 1931-857X |
Publisher: | American Physiological Society |
Date Published: | 2017-08-01 |
Start Page: | F145 |
End Page: | F154 |
Language: | English |
DOI: | 10.1152/ajprenal.00480.2016 |
PROVIDER: | scopus |
PUBMED: | 28381462 |
PMCID: | PMC5582896 |
DOI/URL: | |
Notes: | Review -- Export Date: 5 September 2017 -- Source: Scopus |